|
LIST OF FIGURES |
iv |
|
|
|
|
LIST OF TABLES |
v |
| |
|
Part I. GLOBAL
OVERVIEW
|
1 |
| 1. MARKETSIZE |
1 |
1.1 Regions
|
1 |
| 1.2 Multinational
Corporations |
3 |
1.3 Products
|
3 |
| |
|
| 2. MARKETTRENDS
|
5 |
2.1 New Products
|
5 |
| 2.2 Biotechnology |
5 |
2.3 Generics
|
5 |
2.4 Mergers & Acquisitions
|
6 |
2.5 Research and Development (R&D)
|
6 |
2.6 Counterfeiting
|
7 |
| |
|
| 3. THE MIDDLE EASTMARKET |
8 |
| |
|
| Part II.THE PHARMACEUTICAL
MARKET IN EGYPT 10 |
10 |
| |
|
| 1. OWNERSHIPSTRUCTURE |
11 |
| 1.1 Public Sector
Companies |
12 |
| 1.2 Private Sector
Companies |
14 |
| |
|
| 2. PRODUCTSTRUCTURE |
16 |
| 2.1 Therapeutic
Groups |
16 |
| 2.2 Product Type
Development |
17 |
| |
|
| 3. INVESTMENTIN PHARMACEUTICAS |
17 |
| 3.1 Private Investment
|
17 |
| 3.2 Privatization
Progress |
19 |
| 3.3 Pharmaceutical
Companies on the Stock Exchange |
19 |
| |
|
| 4. INTERNATIONALTRADE |
20 |
| |
|
| 5. MARKETREGULATIONS |
21 |
| 5.1 Intellectual
Property Rights and TRIPS |
21 |
| Data
Exclusivity |
22 |
TRIPS
Implementation
|
22 |
| Famous
Marks |
22 |
| 5.2 Pricing |
23 |
| 5.3 Registration
Regulations and Procedures |
23 |
| 5.4 Import/Export
Regulations |
24 |
| |
|
| Part III. RECENTDEVELOPMENTS |
25 |
| |
|
| 1. CHALLENGES TO DEVELOPMENT |
25 |
| 1.1 Devaluation and Drug Pricing |
26 |
| 1.2 Implementation of Intellectual
Property Rights |
26 |
| 1.3 Marketing |
|
| |
|
| 2. DEVELOPMENTCATALYSTS |
26 |
| 2.1 Government Measures |
27 |
| Pricing Reform |
27 |
| R&D |
28 |
| Regulatory Reform |
28 |
| Counterfeiting |
28 |
| Investment
in Healthcare |
29 |
| Export Promotion |
29 |
| Restructuring of Public
Sector Companies |
30 |
| 2.2 Local Companies' Measures |
30 |
| |
|
| Part IV. CONCLUSION |
31 |
| 1. LOCAL
MARKET ASSESSMENT |
31 |
| SWOT Analysis |
31 |
| |
|
| 2. LOCAL MARKET OUTLOOK |
33 |
| |
|
| 3. FUTURE REFORM MEASURES |
34 |
| |
|
| 4. INVESTMENT POTENTIAL |
35 |
| Export Potential |
36 |
| |
|
| Appendix I |
39 |
